Zhang, Z., Ye, J., Li, H., Gu, D., Du, M., Ai, D., . . . Zhou, G. (2022, October). Neoadjuvant sintilimab and chemotherapy in patients with resectable esophageal squamous cell carcinoma: A prospective, single-arm, phase 2 trial. Frontiers in Immunology.
Chicago Style (17th ed.) CitationZhang, Zhi, et al. "Neoadjuvant Sintilimab and Chemotherapy in Patients with Resectable Esophageal Squamous Cell Carcinoma: A Prospective, Single-arm, Phase 2 Trial." Frontiers in Immunology Oct. 2022.
MLA (9th ed.) CitationZhang, Zhi, et al. "Neoadjuvant Sintilimab and Chemotherapy in Patients with Resectable Esophageal Squamous Cell Carcinoma: A Prospective, Single-arm, Phase 2 Trial." Frontiers in Immunology, Oct. 2022.
Warning: These citations may not always be 100% accurate.